Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Boardroom

Roche Basel Switzerland

Roche gets FDA OKs for Alecensa and Zelboraf

Gains US licences for first-line use in lung cancer and a rare blood cancer

Roche Basel Switzerland

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

Roche Basel Switzerland

Roche biggest pharma R&D spender in PwC survey

Pharma giant on track to spend 21.9% of its total revenue on research this year

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Roche Basel Switzerland

Roche wins CHMP nod for Alecensa licence extensions

Lung cancer monotherapy set for a broader European label

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

Roche - Basel

Roche and J&J picked for ‘revolutionary’ digital health pilot

Firms will line up alongside Apple, Fitbit, Samsung and Verily in FDA pre-certification programme

Roche Basel Switzerland

Roche’s Actemra/RoActemra receives new European approval

EU regulators also pass the Swiss pharma firm’s Gazyvaro

- PMLiVE

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links